Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
Granted 695.0K · Sold 105.2K
Granted 250.0K · Sold 31.4K
Granted 187.5K · Sold 46.3K
Granted 212.5K · Sold 3.0K
Granted 177.5K · Sold 2.9K
Granted 4.7K
Granted 4.7K
Granted 4.7K
Granted 4.7K
Granted 4.7K
Granted 3.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Barrow RobertChief Executive Officer, Director · 6 transactions | +32.3% | 1.10M | 695.0K | — | 105.2K |
| Karlin DanielChief Medical Officer · 6 transactions | +14.8% | 503.3K | 250.0K | — | 31.4K |
| Sullivan MarkChief Legal Officer · 6 transactions | +5.1% | 320.6K | 187.5K | — | 46.3K |
| Roberts BrandiChief Financial Officer · 3 transactions | — | 209.5K | 212.5K | — | 3.0K |
| Wiley Matthew T.Chief Commercial Officer · 3 transactions | — | 174.6K | 177.5K | — | 2.9K |
| Bruhn Suzanne LouiseDirector · 1 transaction | +23.8% | 24.3K | 4.7K | — | — |
| Crystal RogerDirector · 1 transaction | +23.8% | 24.3K | 4.7K | — | — |
| Vallone Carol ADirector · 1 transaction | +28.2% | 21.2K | 4.7K | — | — |
| Gryska David WDirector · 1 transaction | +0.2% | 19.9K | 4.7K | — | — |
| Krebs AndreasDirector · 1 transaction | +30.9% | 19.8K | 4.7K | — | — |
| Adsett RogerDirector · 1 transaction | — | 3.6K | 3.6K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -188.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.